Invitation – Presentation of Sobi’s third quarter results 2016

On 27 October 2016, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2016.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi’s CEO and President, Geoffrey McDonough, and the presentation will be held in English.

The presentation can be followed live, or afterwards on . Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference.

To participate in the telephone conference, please call:
UK: +44 203 008 9809
SE : +46 8 566 426 93
US: +1 855 831 5948

Live audience URL:
(The recording will be made available via the audience URL within three hours after the live broadcast.)  


About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at

For more information please contact  

 Media relations Investor relations
 Linda Holmström, Senior Communications Manager Jörgen Winroth, Vice President, Head of Investor Relations
 +46 70 873 40 95 +1 347-224-0819, +1 212-579-0506, +46 8 697 2135  

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00


Documents & Links